<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PIMECROLIMUS</span><br/>(pim-e-cro-lim'us)<br/><span class="topboxtradename">Elidel<br/></span><b>Classifications:</b> <span class="classification">immunosuppressant</span><br/><b>Prototype: </b>Cyclosporine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% cream</p>
<h1><a name="action">Actions</a></h1>
<p>Pimecrolimus selectively inhibits the inflammatory action of skin cells by blocking T-cell activation and cytokine release.
         It appears to inhibit the production of IL-2, IL-4, IL-10, and interferon gamma in T-cells. It also prevents release of inflammatory
         cytokines and mediators from mast cells after activation by antigen and IgE.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Topically applied to the skin, pimecrolimus produces significant antiinflammatory activity without evidence of skin atrophy.
         (Topical steroids can cause skin atrophy along with their antiinflammatory activity).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term intermittent mild to moderate atopic dermatitis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pimecrolimus or components in the cream; Netherton's syndrome; application to active cutaneous viral infection.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Infection at topical treatment sites; history of untoward effects with topical cyclosporine or tacrolimus; skin papillomas;
         immunocompromised patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Atopic Dermatitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer to affected skin b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Do not apply to any skin surface that appears to be infected.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flu-like symptoms, infections, fever. <span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Gastroenteritis, abdominal pain, nausea, vomiting, diarrhea, constipation. <span class="typehead">Respiratory:</span>  Sore throat, <span class="speceff-common">upper respiratory infection, cough,</span> nasal congestion, asthma exacerbation, rhinitis, epistaxis. <span class="typehead">Skin:</span> <span class="speceff-common"> Burning,</span> irritation, pruritus, skin infection, impetigo, folliculitis, skin papilloma, Herpes simplex dermatitis, urticaria, acne. <span class="typehead">Special Senses:</span> Ear infection, earache, conjunctivitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimal absorption through intact skin. <span class="typehead">Metabolism:</span> No evidence of skin-mediated metabolism, metabolized in liver by CYP 3A. <span class="typehead">Elimination:</span> Primarily excreted in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for and report persistent skin irritation that develops following application of the cream and lasts for more than
            1 wk.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Minimize exposure of treated area to natural or artificial sunlight.</li>
<li>Stop topical application once signs of dermatitis have disappeared. Resume application at the first sign of recurrence.</li>
<li>Wash hand thoroughly after application if hands are not the treatment sites.</li>
<li>Report any significant skin irritation that results from application of the cream.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>